CRS, ICANS, delayed neurotoxicity, and IEC-HS with BCMA CAR T-cell and bispecific T-cell recruiting antibodies
| . | Idecabtagene vicleucel (KarMMa)1 . | Ciltacabtagene autoleucel (CARTITUDE-1)2 . | Teclistamab (MajesTEC-1)3 . | Elranatamab (MagnetisMM-3)4* . | Linvoseltamab (Linker-MM1)5* . | Alnuctamab6* . | ABBV-3837 . |
|---|---|---|---|---|---|---|---|
| CRS | |||||||
| Any grade | 84% | 95% | 72% | 56% | 44% | 53% | 57% |
| Grade ≥3 | 5% | 4% | <1% | 0% | 1% | 0% | 2% |
| ICANS | |||||||
| Any grade | 18%† | 17% | 3% | 3% | 6% | 3% | 2% |
| Grade ≥3 | 3% | 2% | 0% | 0% | 1% | 0% | N/A |
| Delayed neurotoxicity | |||||||
| Any grade | — | 12% | — | — | — | — | — |
| Grade ≥3 | — | 8% | — | — | — | — | — |
| . | Idecabtagene vicleucel (KarMMa)1 . | Ciltacabtagene autoleucel (CARTITUDE-1)2 . | Teclistamab (MajesTEC-1)3 . | Elranatamab (MagnetisMM-3)4* . | Linvoseltamab (Linker-MM1)5* . | Alnuctamab6* . | ABBV-3837 . |
|---|---|---|---|---|---|---|---|
| CRS | |||||||
| Any grade | 84% | 95% | 72% | 56% | 44% | 53% | 57% |
| Grade ≥3 | 5% | 4% | <1% | 0% | 1% | 0% | 2% |
| ICANS | |||||||
| Any grade | 18%† | 17% | 3% | 3% | 6% | 3% | 2% |
| Grade ≥3 | 3% | 2% | 0% | 0% | 1% | 0% | N/A |
| Delayed neurotoxicity | |||||||
| Any grade | — | 12% | — | — | — | — | — |
| Grade ≥3 | — | 8% | — | — | — | — | — |
1. Munshi et al,2 NEJM 2021. 2. Berdeja et al,3 Lancet 2021. 3. Moreau et al,4 NEJM 2022. 4. Bahlis et al,5 ASH 2022 presentation. 5. Bumma et al,6 ASH 2022 presentation. 6. Wong et al,7 ASH 2022 presentation. 7. D'Souza et al,8 JCO 2022.
Data from updated data presented at the 2022 American Society of Hematology Annual Meeting.
Referred to as investigator-identified neurotoxicity.